

# Ursolic acid as a potential agent in alleviating abnormal keratinocyte behavior in psoriasis

Ewa Bielecka<sup>1</sup>, Anna Maksylewicz<sup>1</sup>, Natalia Zubrzycka<sup>1,2</sup>, Krzysztof Nowak<sup>3</sup>, Małgorzata Miastkowska<sup>4</sup>, Tomasz Kantyka<sup>1</sup>

<sup>1</sup> Laboratory of Proteolysis and Posttranslational Modification of Proteins, Małopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, Kraków, Poland

<sup>2</sup> Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, Kraków, Poland

<sup>3</sup> Wellnanopharm Sp. z o.o., Bandtkiego 19, Kraków, Poland



<sup>4</sup> Department of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, 31-155 Kraków, Poland

**ABSTRACT:** Psoriasis is a chronic inflammatory skin disease characterized by excessive proliferation of keratinocytes and infiltration of inflammatory cells into the outer layers of the skin. Observed epidermal hyperplasia and production of pro-inflammatory cytokines by keratinocytes is mainly induced by the action of lymphocytes Th17. Psoriasis treatment focuses on reducing the inflammatory response and limitation of keratinocytes proliferation. Here we report usage of ursolic acid, natural triterpenoid compound present in extracts from herbs and fruits, as an active agent mitigating abnormal keratinocyte behavior typical for psoriasis. Keratinocyte cell line HaCaT treated with cytokine M5 cocktail (IL-1, IL-17A, IL-22, oncostatin M, and TNF- $\alpha$ ), characteristically secreted by psoriatic Th17 lymphocytes, showed increased proliferation and proinflammatory cytokine production, mimicking the disease phenotype. Application of ursolic acid limited M5-induced production of IL-6 and -8. This was accompanied by reduction of other psoriatic markers and by a decrease in the hyperproliferation of HaCaT cells. The latest is likely mediated by non-inflammatory apoptotic cell death of keratinocytes. Our data indicate that ursolic acid can serve as a psoriasis mitigating agent and could be considered as an active ingredient in preparations intended for use as a topical cosmetics.


**Psoriasis** is a relatively common inflammatory skin disease that affects nearly 2-5% of the population. Its clinical symptoms are characterized by an acute inflammatory reaction in the first phase, which turns into a chronic form. Psoriasis is characterized by three typical histological features: (i) epithelial hyperplasia, (ii) dilated, enhanced blood vessels formation in the dermis, (iii) accumulation of inflammatory cells, mainly in the dermis. The detailed mechanism of psoriasis development is not yet clear. Current hypothesis indicate primary activation of the innate immune system, based on the impaired response of keratinocytes, neutrophils and dendritic cells, which leads to the subsequent recruitment of Th17 cells. The disturbance in the functioning of the adaptive immune system including excessive activation of dendritic cells and in turn Th1/Th17 lymphocytes results in the production of cytokines, especially IL-17A, IL-22, TNF $\alpha$  and interferon  $\gamma$ , which generate full clinical outcome of the disease. Current anti-psoriasis treatments focus on reducing the inflammation state and limitation of keratinocyte hyperproliferation.

## INTRODUCTION

## URSOLIC ACID




**Fig 1. Cytotoxicity of ursolic acid at confluent culture of HaCaT keratinocyte cells.** Confluent culture of HaCaT cells were incubated with increasing concentrations of ursolic acid (0-100  $\mu$ M) or mock (DMSO) for 24h. Viability of the cells was evaluated with MTT assay and shown as a percentage of viability of untreated control. Safe concentration of ursolic acid was assessed at the level of 12.5  $\mu$ M. Results are shown as an mean with SEM (one-way Anova with Dunnett post test).




**Fig 2. Ursolic acid decreases IL-6 and IL-8 production in HaCaT cells stimulated with M5 cytokine cocktail.** Confluent cultures of HaCaT cells were stimulated with 1ng/ml of M5 cytokine cocktail (1ng/ml of each IL-1 $\alpha$ , IL-17A, IL-22, TNF- $\alpha$  and Oncostatin M) in the presence of increasing concentrations of ursolic acid (0-10  $\mu$ M). After 24h cell media were collected and analysed for IL-6 and IL-8 levels with ELISA. M5 stimulation induced significant increase in proinflammatory cytokine production as illustrated by the levels of IL-6 (A) and IL-8 (B). Presence of ursolic acid limited the production of above mentioned cytokines by 50% at the highest used concentration of ursolic acid (10  $\mu$ M).

## RESULTS

### IL-6 and IL-8 production after M5 stimulation in the presence of Ursolic acid



**Fig 3. Ursolic acid decreases hyperproliferation of HaCaT cells stimulated with M5 cytokine cocktail.** HaCaT cells were seeded on 96 well plate at the density of 2000 cells/well. Cells were then stimulated with M5 cytokine cocktail (2.5 ng/ml) in the presence of increasing concentration of ursolic acid (0-10  $\mu$ M) in DMEM with 1% FBS. After 72h amount of cells in each sample was estimated using MTT assay. Results are shown as a percentage of untreated control (mean with SEM, one-way Anova with Dunnett posttest). Stimulation of cells with M5 cytokine cocktail increased the proliferation of cells by 40% in comparison to untreated control. Usage of ursolic acid in concentration of 5 $\mu$ M decreased cells hyperproliferation to level of not stimulated control. Concentration of ursolic acid above 10  $\mu$ M ursolic acid caused decreased proliferation of HaCaT cells.



## Conclusions

1. M5 cytokine cocktail (IL-1, IL-17A, IL-22, oncostatin M, and TNF- $\alpha$ ) is a good stimulant inducing psoriasis-like phenotype in keratinocyte cell lines
2. Ursolic acid mitigate proinflammatory cytokin production (IL-6 and IL-8) by HaCaT cells with psoriatic-like phenotype
3. Ursolic acid limits hyperproliferation of HaCaT cells in psoriatic model, probably by mediation of non-inflammatory apoptotic cell death of keratinocytes

The research was funded under the project entitled DEVELOPMENT OF A LINE OF MEDICAL PRODUCTS BASED ON NANO-GEL WITH PROPERTIES RANGING FROM SKIN CARE TO TREATMENT TO ALLEVIATE INFLAMMATORY SKIN CONDITIONS, contract no: RPMP.01.02.01-12-0186/19 implemented by WellNanoPharm Sp. z o.o.

The research has been carried out at the Małopolska Centre of Biotechnology, Jagiellonian University (contract CRUIP UJ nr 1204 z dn. 20.08.2020)